Mediation of inflammation, obesity and fatty liver disease by advanced glycation endoproducts

European Review for Medical and Pharmacological Sciences

Volumn 21, Issue 22, 2017, Pages 5172-5178

  Xiong, D D ^a   Zhang, M ^a   Li, N ^a   Gai, J F ^a   Mao, L ^a   Li, M ^a  

^a Binzhou Central Hospital   (China)

Author keywords

Advanced glycosylation end products; Inflammatory cytokines; Obesity fatty liver

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; HEPATITIS; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HISTOPATHOLOGY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TISSUE; LIVER WEIGHT; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MALE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STAINING; TOTAL CHOLESTEROL LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; INFLAMMATION; LIVER; LIVER FUNCTION TEST; METABOLISM; ORGAN SIZE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, LDL; FATTY LIVER; GLYCATION END PRODUCTS, ADVANCED; INFLAMMATION; INTERLEUKIN-6; LIVER; LIVER FUNCTION TESTS; MALE; OBESITY; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85042849747     PISSN: 11283602     EISSN: 22840729     Source Type: Journal    
DOI: 10.26355/EURREV_201711_13835     Document Type: Article

References (22)

1. Qin XD, Qian Z, Vaughn Mg, TreVaThan e, eMo B, Paul g, ren Wh, hao YT, Dong gh. Gender-specific differences of interaction between obesity and air pollution on stroke and cardiovascular diseases in Chinese adults from a high pollution range area: a large population based cross sectional study. Sci Total Environ 2015; 529: 243-248.
2. Chang CJ, Jian DY, lin MW, Zhao JZ, ho lT, Juan CC. Evidence in obese children: contribution of hyperlipidemia, obesity-inflammation, and insulin sensitivity. PLoS One 2015; 10: e0125935.
3. King WC, Chen JY, BonD DS, Belle Sh, CourCoulaS aP, PaTTerSon eJ, MiTChell Je, inaBneT WB, DaKin gF, FluM Dr, CooK B, WolFe BM. Objective assessment of changes in physical activity and sedentary behavior: Pre- through 3 years post-bariatric surgery. Obesity (Silver Spring) 2015; 23: 1143-1150.
4. FeDeriCo a, Dallio M, MaSarone M, PerSiCo M, loguerCio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. Eur Rev Med Pharmacol Sci 2016; 20: 4731-4741.
5. XanThaKoS Sa, JenKinS TM, Kleiner De, BoYCe TW, MourYa r, KarMS r, BranDT Ml, harMon CM, helMraTh Ma, MiChalSKY MP, CourCoulaS aP, Zeller Mh, inge Th, Teen-LABS Consortium. High prevalence of nonalcoholic fatty liver disease in adolescents undergoing bariatric surgery. Gastroenterology 2015; 149: 623-634.
6. PaCiFiCo l, BonCi e, Di MarTino M, VerSaCCi P, anDreoli g, SilVeSTri lM, ChieSa C. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2015; 25: 734-741.
7. CeleBi g, genC h, gurel h, SerToglu e, Kara M, TaPan S, aCiKel C, KarSlioglu Y, erCin Cn, Dogru T. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J Gastroenterol 2015; 21: 139-145.
8. luCKhoFF hK, Kruger FC, KoTZe MJ. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: clinical application in developing countries. World J Hepatol 2015; 7: 1192-1208.
9. Chou CY, Yang YC, Wu JS, Sun ZJ, lu Fh, Chang CJ. Non-alcoholic fatty liver disease associated with increased arterial stiffness in subjects with normal glucose tolerance, but not pre-diabetes and diabetes. Diab Vasc Dis Res 2015; 12: 359-365.
10. BaSaranoglu M, CanBaKan B, YiDiZ K, CeYlan B, BaY-Sal B, uYSal o, SenTurK h. Fatty liver disease might increase the risk of abdominal operation in patients with fatty liver and the prevalence of cancer in firstdegree relatives. Turk J Gastroenterol 2014; 25 Suppl 1: 138-141.
11. TeiCherT T, hellWig a, PeBler a, hellWig M, VoSSoughi M, Sugiri D, VierKoTTer a, SChulTe T, FreunD J, roDen M, hoFFMann B, SChiKoWSKi T, luCKhauS C, KraMer u, henle T, herDer C. Association between advanced glycation end products and impaired fasting glucose: results from the SALIA Study. PLoS One 2015; 10: e0128293.
12. Zhao DC, lu hW, huang Zh. Association between the receptor for advanced glycation end products gene polymorphisms and cancer risk: a systematic review and meta-analysis. J BUON 2015 20: 614-624.
13. reMPel lC, FinCo aB, MaCiel ra, BoSQueTTi B, alVarenga lM, SouZa WM, PeCoiTS-Filho r, STinghen ae. Effect of PKC-beta signaling pathway on expression of MCP-1 and VCAM-1 in different cell models in response to advanced glycation end products (AGEs). Toxins (Basel) 2015; 7: 1722-1737.
14. SeBeKoVa K, STuMer M, FaZeli g, Bahner u, STaB F, heiDlanD a. Is vitamin d deficiency related to accumulation of advanced glycation end products, markers of inflammation, and oxidative stress in diabetic subjects? Biomed Res Int 2015; 2015: 958097.
15. Chen PM, gregerSen h, Zhao JB. Advanced glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats. World J Diabetes 2015; 6: 662-672.
16. ChheDa TK, ShiVaKuMar P, SaDaSiVan SK, ChanDeraSeKharan h, MooleMaTh Y, ooMMen aM, MaDanahalli Jr, MariKunTe VV. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis-a novel animal model. BMC Gastroenterol 2014; 14: 89
17. orMan D, VarDi n, aTeS B, TaSliDere e, elBe h. Aminoguanidine mitigates apoptosis, testicular seminiferous tubules damage, and oxidative stress in streptozotocin-induced diabetic rats. Tissue Cell 2015; 47: 284-290.
18. KanDel-KFir M, alMog T, ShaiSh a, ShloMai g, anaFi l, aViV C, BarShaCK i, groSSKoPF i, haraTS D, KaMari Y. Interleukin-1alpha deficiency attenuates endoplasmic reticulum stress-induced liver damage and CHOP expression in mice. J Hepatol 2015; 63: 926-933.
19. Tan DY, Shi hY, li CP, Zhong Xl, Kang M. Effect of nuclear factor-kappaB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21: 5877-5883.
20. PraVeen raJ P, goMeS rM, KMar S, SenThilnaThan P, KarThiKehYan P, ShanKar a, PalaniVelu C. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: «NASHOST» prospective observational trial. Surg Obes Relat Dis 2015; 11: 1315-1322.
21. ganJi Sh, KaShYaP Ml, KaManna VS. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: impact on non-alcoholic fatty liver disease. Metabolism 2015; 64: 982-990.
22. gurel h, genC h, CeleBi g, SerToglu e, CiCeK aF, KaYaDiBi h, erCin Cn, Dogru T. Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatter liver disease. Eur Rev Med Pharmacol Sci 2016; 20: 4305-4312.